- Coordinates
- PDB Format
- Method
- ELECTRON MICROSCOPY
- Oligo State
- hetero-3-2-2-mer
- Ligands
- 10 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)(Non-covalent)
- 3 x NAG- NAG- BMA: beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
NAG-NAG-BMA.2: 2 residues within 4Å:- Chain A: E.281, N.282
No protein-ligand interaction detected (PLIP)NAG-NAG-BMA.3: 2 residues within 4Å:- Chain A: N.331, Q.580
No protein-ligand interaction detected (PLIP)NAG-NAG-BMA.7: 2 residues within 4Å:- Chain A: K.558
- Chain B: N.282
No protein-ligand interaction detected (PLIP)- 1 x NAG- NAG- BMA- MAN- MAN: alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(3-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 1 x NAG- NAG- BMA- FUC: beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-[alpha-L-fucopyranose-(1-6)]2-acetamido-2-deoxy-beta-D-glucopyranose
- 1 x NAG- NAG- BMA- MAN- MAN- FUC: alpha-D-mannopyranose-(1-3)-alpha-D-mannopyranose-(1-6)-beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-[alpha-L-fucopyranose-(1-6)]2-acetamido-2-deoxy-beta-D-glucopyranose
- 1 x MAN- MAN: alpha-D-mannopyranose-(1-6)-alpha-D-mannopyranose(Non-functional Binders)
- 28 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)(Non-functional Binders)(Non-covalent)
NAG.18: 2 residues within 4Å:- Chain A: Y.28, N.61
Ligand excluded by PLIPNAG.19: 3 residues within 4Å:- Chain A: N.122, A.123, T.124
Ligand excluded by PLIPNAG.20: 2 residues within 4Å:- Chain A: N.164, N.165
Ligand excluded by PLIPNAG.21: 1 residues within 4Å:- Chain A: N.616
Ligand excluded by PLIPNAG.22: 2 residues within 4Å:- Chain A: H.655, N.657
Ligand excluded by PLIPNAG.23: 4 residues within 4Å:- Chain A: S.708, N.709
- Chain B: I.794, D.796
Ligand excluded by PLIPNAG.24: 5 residues within 4Å:- Chain A: N.717, F.718, T.719, A.1070
- Ligands: NAG.25
Ligand excluded by PLIPNAG.25: 1 residues within 4Å:- Ligands: NAG.24
Ligand excluded by PLIPNAG.26: 3 residues within 4Å:- Chain A: E.1072, N.1074
- Ligands: FUC.27
Ligand excluded by PLIPNAG.28: 1 residues within 4Å:- Chain B: N.61
Ligand excluded by PLIPNAG.29: 3 residues within 4Å:- Chain B: N.122, T.124, V.127
Ligand excluded by PLIPNAG.30: 1 residues within 4Å:- Chain B: N.165
Ligand excluded by PLIPNAG.31: 4 residues within 4Å:- Chain B: T.114, G.232, I.233, N.234
Ligand excluded by PLIPNAG.32: 1 residues within 4Å:- Chain B: N.331
Ligand excluded by PLIPNAG.34: 2 residues within 4Å:- Chain B: N.616, T.618
Ligand excluded by PLIPNAG.35: 1 residues within 4Å:- Chain B: N.657
Ligand excluded by PLIPNAG.36: 2 residues within 4Å:- Chain B: N.709
- Chain C: D.796
Ligand excluded by PLIPNAG.37: 2 residues within 4Å:- Chain B: N.717
- Ligands: NAG.38
Ligand excluded by PLIPNAG.38: 1 residues within 4Å:- Ligands: NAG.37
Ligand excluded by PLIPNAG.39: 4 residues within 4Å:- Chain B: N.801, S.803, Q.804
- Ligands: NAG.40
Ligand excluded by PLIPNAG.40: 1 residues within 4Å:- Ligands: NAG.39
Ligand excluded by PLIPNAG.41: 2 residues within 4Å:- Chain C: Y.28, N.61
Ligand excluded by PLIPNAG.42: 2 residues within 4Å:- Chain C: N.122, T.124
Ligand excluded by PLIPNAG.43: 2 residues within 4Å:- Chain C: N.331, Q.580
Ligand excluded by PLIPNAG.44: 2 residues within 4Å:- Chain C: N.616, T.618
Ligand excluded by PLIPNAG.45: 1 residues within 4Å:- Chain C: N.657
Ligand excluded by PLIPNAG.46: 1 residues within 4Å:- Chain C: N.709
Ligand excluded by PLIPNAG.47: 3 residues within 4Å:- Chain C: N.801, S.803, Q.804
Ligand excluded by PLIP- 3 x FUC: alpha-L-fucopyranose(Non-covalent)
FUC.27: 2 residues within 4Å:- Chain A: N.1074
- Ligands: NAG.26
1 PLIP interactions:1 interactions with chain A- Hydrophobic interactions: A:N.1074
FUC.33: 4 residues within 4Å:- Chain B: N.343, T.345
- Ligands: NAG-NAG-BMA-MAN-MAN.8, NAG-NAG-BMA-MAN-MAN.8
1 PLIP interactions:1 interactions with chain B- Hydrogen bonds: B:T.345
FUC.48: 2 residues within 4Å:- Chain C: N.1074
- Ligands: NAG-NAG.16
No protein-ligand interaction detected (PLIP)- 2 x MAN: alpha-D-mannopyranose(Non-covalent)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Fedry, J. et al., Structural insights into the cross-neutralization of SARS-CoV and SARS-CoV-2 by the human monoclonal antibody 47D11. Sci Adv (2021)
- Release Date
- 2021-05-19
- Peptides
- Spike glycoprotein: ABC
47D11 neutralizing antibody heavy chain: DF
47D11 neutralizing antibody light chain: EG - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
BC
CD
DF
HE
EG
L
- Coordinates
- PDB Format
- Method
- ELECTRON MICROSCOPY
- Oligo State
- hetero-3-2-2-mer
- Ligands
- 10 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)(Non-covalent)
- 3 x NAG- NAG- BMA: beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 1 x NAG- NAG- BMA- MAN- MAN: alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(3-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 1 x NAG- NAG- BMA- FUC: beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-[alpha-L-fucopyranose-(1-6)]2-acetamido-2-deoxy-beta-D-glucopyranose
- 1 x NAG- NAG- BMA- MAN- MAN- FUC: alpha-D-mannopyranose-(1-3)-alpha-D-mannopyranose-(1-6)-beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-[alpha-L-fucopyranose-(1-6)]2-acetamido-2-deoxy-beta-D-glucopyranose
- 1 x MAN- MAN: alpha-D-mannopyranose-(1-6)-alpha-D-mannopyranose(Non-functional Binders)
- 28 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)(Non-functional Binders)(Non-covalent)
- 3 x FUC: alpha-L-fucopyranose(Non-covalent)
- 2 x MAN: alpha-D-mannopyranose(Non-covalent)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Fedry, J. et al., Structural insights into the cross-neutralization of SARS-CoV and SARS-CoV-2 by the human monoclonal antibody 47D11. Sci Adv (2021)
- Release Date
- 2021-05-19
- Peptides
- Spike glycoprotein: ABC
47D11 neutralizing antibody heavy chain: DF
47D11 neutralizing antibody light chain: EG - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
BC
CD
DF
HE
EG
L